Literature DB >> 33904110

The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients.

Chien-Wei Peng1,2, Wen-Juei Jeng3,4.   

Abstract

Entities:  

Year:  2021        PMID： 33904110     DOI： 10.1007/s12072-021-10168-9

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  5 in total

1.  Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir.

Authors:  Jung Woo Shin; Seok Won Jung; Seung Bum Lee; Byung Uk Lee; Bo Ryung Park; Eun Ji Park; Neung Hwa Park
Journal:  Am J Gastroenterol       Date:  2018-06-08       Impact factor: 10.864

Review 2.  Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.

Authors:  Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2019-09-26       Impact factor: 6.047

3.  Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).

Authors:  Kin Seng Liem; Scott Fung; David K Wong; Colina Yim; Seham Noureldin; Jiayun Chen; Jordan J Feld; Bettina E Hansen; Harry L A Janssen
Journal:  Gut       Date:  2019-08-28       Impact factor: 23.059

4.  Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.

Authors:  Maria Buti; David K Wong; Edward Gane; Robert Flisiak; Michael Manns; Kelly Kaita; Harry L A Janssen; Marjoleine Op den Brouw; Belinda Jump; Kathryn Kitrinos; Gerald Crans; John Flaherty; Anuj Gaggar; Patrick Marcellin
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-02-20

5.  Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.

Authors:  Wen-Juei Jeng; Yi-Cheng Chen; Rong-Nan Chien; I-Shyan Sheen; Yun-Fan Liaw
Journal:  Hepatology       Date:  2018-05-06       Impact factor: 17.425
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.